Cholecalciferol Comedication in IBD - the 5C Study
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Vitamin D deficiency (defined as 25(OH)-vitamin D serum level <50 nmol/ l) is associated with
irritable bowel disease (IBD). National guidelines recommend the administration of 800 -4000
IU cholecalciferol daily for an effective treatment, especially during the winter (poor sun
exposition). Cumulative intermittent administration monthly or weekly is possible. The study
aims to compare inflammation activity (primary outcome) after monthly or weekly treatment
with soft capsules containing 24'000 IU cholecalciferol compared to no vitamin D
supplementation. Quantification of 25(OH)-vitamin D serum values is a secondary outcome. The
investigators will use newly developed soft capsules.